Introduction
Infectious complications are the main cause of death in hematological patients undergoing aggressive chemotherapy or high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT). Early commencement of empirical antibiotic therapy can reduce the associated morbidity and mortality. 1, 2 Controlled studies have shown that no differences are demonstrable with regard to response to therapy when the results of combined antibiotic therapy are compared with those of single-agent therapy. 3, 4 Ceftazidime, a third-generation cephalosporin, has been examined in a number of studies as single-agent therapy 5 and combined therapy. 6 Ceftazidime displays very good efficacy against Gramnegative bacteria including Pseudomonas aeruginosa but, like most cephalosporin antibiotics, only limited activity against Gram-positive bacteria.
Piperacillin -a synthetic broad-spectrum penicillin -in combination with the potent b-lactamase inhibitor tazobactam has been available for the empirical initial therapy of febrile neutropenic patients since 1993. Piperacillin/ tazobactam was chosen for the comparative single-agent arm of this study because of its broad antimicrobial spectrum -which includes P. aeruginosa -and its excellent efficacy against Gram-positive pathogens including Streptococci. In vitro studies in which piperacillin/tazobactam was tested against 365 bacteremic isolates of neutropenic patients showed efficacy comparable to that of ceftazidime with regard to Gram-negative bacteria and superior to that of ceftazidime with regard to Gram-positive bacteria. 7 In the EORTC 9 study, piperacillin/tazobactam combined with amikacin was tested as empirical therapy in febrile neutropenic patients. The combination proved to be successful in comparison to ceftazidime plus amikacin, achieving defervescence in a shorter period of time. 8 Kelsey et al. 9 performed a noncomparative study with piperacillin/ tazobactam plus gentamicin in 44 febrile neutropenic patients with hematological malignancies in which 67% of the patients responded to the combination therapy.
We report here on the first randomized study to examine piperacillin/tazobactam as single-agent therapy in comparison to ceftazidime for febrile neutropenic patients with acute leukemia or following HDCT and PBSCT. The purpose of the randomized, prospective study was to compare the equivalence, safety, efficacy and tolerability of piperacillin/tazobactam with those of ceftazidime as empirical antibiotic therapy.
Patients and methods
The study was performed at the Department of Internal Medicine V of the University of Heidelberg.
Patient-selection criteria
Patients recruited to the study were either suffering from acute leukemia or had undergone HDCT and PBSCT. A neutrophil count of o0.5/nl was required at the start of treatment (at the latest 24 h after admission to the study). Patients with fever 438.5 or 4381C on two occasions within 12 h were admitted. The fever was required not to be associated with the underlying disease, transfusion of blood products or administration of cytokines. The existence of an allergy to any of the study preparations was regarded as an exclusion criterion. In addition, patients with severe impairment of liver function or HIV disease, and dialysisdependent patients were excluded. It was decided to allow to include the same patient several times during a series of neutropenic episodes, assuming that subsequent neutropenic episodes correspond to independent observations. Patients received oral anti-infection prophylaxis with either trimethoprim-sulfometoxazol or ciprofloxacin, and antimycotic prophylaxis with amphotericin-B suspension or fluconazole.
Ethics
The study protocol was approved by the ethics committee responsible and conducted in compliance with the Declaration of Helsinki and the guidelines of Good Clinical Practice. All patients gave written informed consent to participate in the study.
Randomization procedure
Randomization was performed by the team of pharmacists providing a 24-h service, by means of a randomization list with which patients were assigned randomly to the two arms with equal probability. Owing to the inclusion criteria, it was possible for the same patient to be randomized several times. Randomization numbers were assigned to the patients in ascending order. Treatment group I received single-agent therapy with ceftazidime (2 g every 8 h as a short-term infusion over 30 min; in cases of impaired kidney function the dose was reduced in accordance with the manufacturer's data sheet). Treatment group II received single-agent therapy with piperacillin/ tazobactam (4.5 g every 8 h as a short-term infusion over 30 min; in cases of impaired kidney function the dose was reduced in accordance with the manufacturer's data sheet). According to the study protocol it was planned to include a total of 588 patients evaluable for response to therapy during an accrual period of 3 years. The study was closed in November 2003 after 3.5 years accrual, after it became obvious that the required number of 588 patients would not be achieved within a reasonable amount of time. At that time a total of 243 evaluable patients were included into the study.
Treatment regimes
In keeping with the randomization list, the patients were randomized either in group I (single-agent therapy with ceftazidime 3 Â 2 g every 8 h) or group II (single-agent therapy with piperacillin/tazobactam 3 Â 4.5 g every 8 h).
Patients were examined daily by the physician and the first evaluation of the therapy was performed 72 h after the start of antibiotic therapy. The initial treatment was retained in the event of defervescence (freedom from fever for 5 days or neutrophils 41.0/nl). If the fever did not subside and/or the clinical symptoms deteriorated, supplementary treatment with vancomycin was given (2 Â 1 g daily every 12 h). A further evaluation was carried out 48-72 h later. If the fever persisted, the initial treatment was replaced by imipenem/cilastin (4 Â 0.5 g daily). Systemic amphotericin-B treatment (0.7-1 mg/kg body weight) was instituted if radiology revealed pulmonary infiltration. An antibiogram was obtained and the therapy modified accordingly in the event of microbiologically documented infection (MDI).
Examinations at the start of the study After a clinical examination, at least two separate venous blood cultures (aerobic/anaerobic) were drawn within 30-60 min, and an additional blood culture from a central venous catheter in patients with a central venous access. Clean catch urine cultures were taken whenever a urinary tract infection was suspected. Thoracic organs were X-rayed in two projections. Further imaging procedures (HR-CT, X-ray of the paranasal sinuses, upper abdominal sonography) were performed at intervals in the event of clinical symptoms. Additional diagnostic tests were undertaken only in cases of persisting clinical symptoms (e.g. stool cultures including tests for Clostridium difficile enterotoxin A and B, wound swabs, and needle aspirates from abscess, etc.).
Definition of infectious events
Definition of infectious events was based on the Consensus Conference of the Immune-compromised Host Society. 10 Fever of unknown origin Newly occurring fever 438.5 or 438.01C lasting 1 h or twice within 12 h with no clinical or microbiological infection findings to indicate the direction.
Clinically documented infection
Clinically documented infection (CDI) was defined as fever in association with a diagnostically clearly localized finding, for example, pneumonia.
MDI with or without bacteremia
A MDI was regarded as present if, in addition to a localized focus of infection, a clinically relevant pathogen could be isolated from blood cultures or other relevant sample sites. At least two positive blood cultures from separate samples were required for coagulase-negative Staphylococci and Corynebacterium spp. to be judged as relevant, while a single isolate was regarded as contamination. In the case of pulmonary infiltrates, detection of a relevant pathogen from blood cultures or bronchoalveolar lavage was regarded as reliable, while throat swabs and sputum were considered relevant only if obligate pathogens were isolated in direct temporal association with the occurrence of pulmonary infiltrates. A single positive test for C. difficile enterotoxin A and B fulfilled the diagnostic criteria for antibiotic-associated diarrhea, while other possible enteropathogenic bacteria had to be isolated in at least two consecutive fecal specimens.
Duration of treatment
Length of treatment depended on duration and severity of the granulocytopenia as the leading risk factor for the severity and course of infectious complications following chemotherapy and PBSCT. The first time point for assessing clinical results of treatment was set in both treatment groups at 72 h after the start of therapy. The initial therapy was continued for at least 5 days (or until the granulocytes increased to 41.0/nl) if the treatment was successful. If no improvement was achieved with the initial therapy, treatment was escalated after 72 h (3 full days of therapy). In line with the time course of the initial therapy, subsequent treatment was also assessed after 48-72 h and continued depending on the status of the granulocytopenia. An observation period of 7 days was required after the end of the antimicrobial treatment to be able to detect recurrent or secondary infection. The follow-up observation could also be carried out within the framework of outpatient or GP supervision.
Definition of therapeutic response
The result of treatment was assessed (a) within 72 h after the start of antimicrobial therapy (initial response), (b) on completion of the study therapy (definitive response) and (c) at the end of the study.
Successful treatment without modification. Normalization of body temperature to below 381C and elimination of all clinical symptoms of infection and of any documented pathogens by the initial therapy with piperacillin/tazobactam or ceftazidime and no new signs of infection within 1 week after the end of the antimicrobial therapy.
Successful treatment after modification. Elimination of all clinical symptoms of infection and of the infective agent after appropriate modification of the therapy or renewed fever of unknown origin (FUO) after 72 h following an initial response, and extension of the initial therapy with this substance, which is directed against a different spectrum of infective agents than the initial therapy, and stable defervescence after such modification. Therapy failure. Therapy was considered to have failed if extension, modification or replacement of the initial therapy with another antimicrobial therapy failed to elicit an initial response in the absence of a secondary infection.
Deaths. All patients who died during the study therapy or within 7 days after the end of therapy were counted as deaths within the study. The possibility of a causal association with the infection under treatment or with any toxicity from the antimicrobial substances employed was to be investigated.
Toxicity
Nephrotoxicity and hepatotoxicity, which were defined as an increase in serum creatinine, transaminases, bilirubin or alkaline phosphatase by at least twice the upper normal limit, were studied by means of laboratory analysis. Side effects were entered in the case report forms and an association with the study drugs was assessed as definite, probable, possible, improbable or definitely nonexistent.
Statistics
The primary task of the study was to test noninferiority of treatment group II (single-agent therapy with piperacillin/ tazobactam) compared to treatment group I (single-agent therapy with ceftazidime) with respect to therapeutic response. Thus, if p I and p II are the response rates of the two treatments, the goal is to test the null hypothesis of inferiority, p II op I -d 0 , against the one-sided alternative hypothesis of noninferiority, p II Xp I -d 0 , for a prespecified noninferiority margin d 0 40. In this study, a noninferiority margin d 0 ¼ 10% was chosen. A score test according to Chan 11 was used. In addition, an exact test for differences between response probabilities was performed using Pearson's w 2 test statistic. A Type-I error value of a ¼ 0.05 was chosen for all tests.
All statistical computations were performed using the software package StatXact, version 6 (Cytel Software Corporation, Cambridge, MA, USA).
Results
Characteristics of the study population Two hundred and forty-three patients (219 individuals) who had undergone PBSCT or were suffering from an acute leukemia were recruited to this study from February 2000 to November 2003. Antibiotic prophylaxis was given with either ciprofloxacin (2 Â 500 mg per day) or trimethoprim-sulfomethoxazol (2 Â 160/800 mg per day). Of the 243 patients, 57 (23.5%) did not develop fever in the neutropenic phase. Twenty-five patients (10.3%) were not evaluable because the antibiotic treatment was commenced prior randomization to the treatment arms. Thus, 74 patients who received ceftazidime (group I) and 87 patients who received piperacillin/tazobactam (group II) were suitable for evaluation. Patients' characteristics are shown in Table 1 . No differences existed between the two treatment groups with regard to any of the characteristics. The majority of patients in both groups was suffering from multiple myeloma and had undergone PBSCT (n ¼ 43 in group I and n ¼ 49 in group II).
In addition, seven patients in group I and nine patients in group II who were suffering from acute leukemia were admitted to the study. Fifteen patients in group I and 21 patients in group II exhibited NHL. Patients who had undergone PBSCT because of solid tumors, Hodgkin's disease or AL amyloidosis and myeloproliferative disease formed a small subgroup of the study population.
The median duration of the neutropenia was 9 days (range 1-36 days) in group I and likewise 9 days (range 1-29 days) in group II. The number of days with fever and the length of the antibiotic therapy did not differ considerably in the two groups.
Causes of fever
No cause of the fever was found in 30 patients in group I and 41 patients in group II (Table 2) ; the fever was classified as 'FUO'. Isolated bacteremias occurred in 36 patients (49%) of group I and in 34 patients (39%) of group II. Mainly Gram-positive pathogens were demonstrated in both groups (group I 32 Gram-positive agents, group II 38 Gram-positive agents). Gram-negative pathogens were found in 13 patients in group I and in 13 patients of group II. Pathogens isolated from blood cultures are shown in Table 3 . Mixed cultures were isolated from the blood culture of nine patients in group I and 17 patients of group II, respectively. A CDI was present in eight patients of group I and in 12 patients of group II. A pathogen was also demonstrated in the blood culture of three vs eight of these patients with CDI.
Two patients of group I and three patients of group II developed pseudomembranous colitis during the study.
One patient of group I and one patient of group II died, the latter from Pseudomonas sepsis 2 days after the start of the antibiotic therapy, the former from pneumonia 10 days after the start of the antibiotic therapy.
Results and response rates to first-and second-line treatment Fifty-seven of the 243 patients (23.5%) did not develop fever in the neutropenic phase. These patients were given antibiotic prophylaxis consisting either of ciprofloxacin (n ¼ 11) or of trimethoprim-sulfomethoxazol (n ¼ 46). These patients did not differ from those who developed fever in regard to age, diagnosis and duration of the neutropenia.
Forty-one of 74 patients (55%) in group I and 46 of 87 patients (53%) in group II responded to the first-line treatment ceftazidime or piperacillin-tazobactam. Noninferiority of group II could not be shown (P ¼ 0.17). The one-sided 95% confidence bound for the difference in responses was 15.5%. In addition, no statistically significant difference was demonstrable between the two treatment groups (P ¼ 0.75) concerning inferiority. Extension of the primary therapy with vancomycin occurred with equal frequency in both groups (n ¼ 33 group I, n ¼ 41 group II). An additional 14 patients of group I (19%) and 21 patients of group II (24%) became afebrile after the addition of vancomycin (Table 4) . After extension with vancomycin the response rate in group II was noninferior to the response rate in group I (P ¼ 0.04; the one-sided upper confidence Neutropenic fever in patients with acute leukemia or following stem cell transplantation C Harter et al bound for p I-p II was now 9%). Further modifications to treatment were required in 18 patients of group I (25%) and in 19 patients of group II (22%). When response to therapy is viewed in relation to the cause of the fever (Table 5) , no difference between treatment groups can be seen even with respect to the gram-positive pathogens. Response with regard to Gramnegative infections tended to be better in the group treated with ceftazidime than in group II: Seven of 13 patients with Gram-negative pathogens in group I became afebrile in response to single-agent therapy with ceftazidime, compared to only four of 13 in group II (Table 3) . However, this difference was not statistically significant (P ¼ 0.43).
Discussion
The concept of empirical antibiotic therapy was developed more than 30 years ago. In 1962, Curtin and Marshall realized that, 'in some patients, therapy must be instituted before the bacteriological data are available'. 12 Several combined treatments -for the greater part broad-spectrum b-lactames plus aminoglycoside -have been tested in the last 20 years. Single-agent treatments were employed as broad-spectrum b-lactames, such as ceftazidime and imipenem became available. Pizzo et al. 13 published the first large-scale randomized study involving single-agent therapy. They compared ceftazidime singleagent therapy with the combination of carbenicillin, cephalotin and gentamicin. The treatments proved to be equally effective, with failure rates of only 5 and 4%, respectively. Many subsequent studies in which a singleagent treatment was compared with a combined treatment failed to show any significant difference in the success rates. In most cases, the single agent employed was ceftazidime or imipenem. Data on cefepime and meropenem as singleagent therapy have also been published. 4, 14, 15 We compared piperacillin/tazobactam with its broad antibacterial activity and the inhibitor for b-lactamases with single-agent treatment with ceftazidime. Only those patients were recruited to the study who had either undergone HDCT and PBSCT or who were suffering from an acute leukemia. In 1998, a randomized study comparing piperacillin/ tazobactam single-agent therapy with ceftazidime in combination with amikacin in neutropenic cancer patients was published by Hess et al. 16 Response rates to the singleagent treatments in our patients were comparable in both groups (group I 55 vs 53% group II). Supplementation with vancomycin was done with equal frequency in both groups. When the glycopeptide antibiotic was added to the regimen of patients who were still febrile after 72 h, a further 14 patients of group I and 21 patients of group II became afebrile. Thus, the results are comparable to other data from the literature 17, 18 and to our own data in previously published papers. 19, 20 Antibiotic therapy was discontinued when the patients displayed a body temperature below 381C on 5 consecutive days, even if they were still neutropenic. In other studies, treatment was not discontinued until after 10 afebrile days, or antibiotic treatment was continued until the granulocyte count increased to values above 0.5/nl. The strategy of discontinuing antibiotic therapy after just 5 afebrile days helps to minimize selection out of fungi, and also contributes to cost-saving.
Our results are comparable to those from a study by the EORTC comparing piperacillin/tazobactam plus amikacin with ceftazidime plus amikacin as empirical therapy in neutropenic patients. 8 The reason for the high response rates in Hess's study 16 is that he used different definitions of therapeutic success from ours. In our study and as well as in the EORTC study, every modification of the initial therapeutic regime was classified as a failure. In the study by Hess, vancomycin therapy became an additional constituent part of the study medication after 48 h in line with predetermined criteria, and it was this that resulted in the high response rates of 82%. The main end point of this study was the success due to modification.
The generally high success rate of single-agent therapy may, to a certain extent, be the consequence of microbiological changes, for example, the occurrence of Grampositive pathogens, which are associated with much lower morbidity and mortality. 21 Bacteremias occurred in 49% of the febrile episodes in group I and in 39% of those in group II. This rate is higher than that in the IATCG-EORTC studies 8 and 9, 22 in which the rate of bacteremias was 22%. The difference can possibly be explained by the fact that the majority of our patients had been fitted with a central venous catheter and by antibiotic prophylactic strategies with a higher efficiency against Gram-negative bacteria. In the EORTC study 1, which ran from 1973-1978, the ratio of Gram-negative to Gram-positive bacteremias was 71-29%. A reversal of these figures has been observed over the last few decades, so that Gram-positive pathogens are now the predominant infective agents. Our results, with rates of 30% Gramnegative bacteremias in group I and 26% in group II, agree with those in the IATCG-EORTC studies 8 and 9, which showed rates of 31 and 33%, respectively.
CDIs occurred in eight patients of group I and in 12 patients of group II. Although 94% were suffering from an underlying hematological disease, the low rate of systemic invasive mycosis is not surprising because the number of patients with acute leukemia was small. Systemic antimycotic treatment was started in only four patients. Additional therapy with vancomycin was given in 45% of the febrile events in group I and in 47% of those in group II. These figures agree with those of a study in which meropenem was compared with ceftazidime plus amikacin. 14 The trend towards low mortality secondary to infections has been documented worldwide. At the Jule Bordet Institute, a decrease of mortality during febrile neutropenia from 24 to 12% was observed in patients admitted to the consecutive IATCG EORTC studies in the course of the last 20 years. 22, 23 The latest IATCG-EORTC studies 7, 9 and 11 show a total mortality of between 5 and 12%, with the infection-related mortality lying between 1 and 3%. 8, 14, 24 The infection-related mortality in our study -1.25% -is extremely low.
Toxic effects and side effects caused by the study treatments were mild and included skin rashes and diarrhea. Anand et al. 25 stated that third-generation cephalosporin use is correlated with the development of C. difficile associated diarrhoea; ceftazidime was highly significantly associated (Po0.01) with more cases than expected by usage alone vs ticarcillin/clavulanate. Compared to the literature the incidence of C. difficile diarrhoea was low in our trial. Also, no difference in the incidence of C. difficile diarrhoea (ceftazidime group: two patients (3%), piperacillin/tazobactam group: three patients (3%)) was observed. In our study, only patients with diarrhoea underwent an investigation for C. difficile toxin. Low duration of hospitalization (o3 weeks) and only investigation for the toxin may explain the low rate of C. difficile positivity in our study. Although an increasing incidence of antimicrobial resistance among both Gram-positive and Gram-negative pathogens isolated from patients with neutropenia is described in the literature, 26 we failed to observe this trend in our department.
The results of this study show that piperacillin/tazobactam and ceftazidime are of equal value in the treatment of neutropenic fever in patients following high-dose chemotherapy and autologous peripheral blood stem-cell transplantation or in patients with acute leukemia. Meanwhile, direct costs are equal for both antibiotic agents. Indirect costs concerning infusion material and working time for treatment (three times/day) are the same for both treatment regimes. These therapeutic guidelines with restricted use of glycopeptides 27 and early discontinuation of intravenous empirical antibiotic therapy after 5 afebrile days contribute significantly to the reduction of costs and toxic side effects, counter the development of resistance and minimize the positive selection of fungi.
